Drugs / TGFbeta resistant LMP-specific CTLs
TGFbeta resistant LMP-specific CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00368082 | Apr 2006 → Sep 2013 overdue | Hodgkins lymphoma, non-Hodgkin lymphoma | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFbeta resistant LMP-specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00368082 ↗ |
| Known as | DNR-CTL | “special immune system cells called TGFb-resistant LMP-specific cytotoxic T lymphocytes (DNR-CTL), a new experimental therapy.” NCT00368082 ↗ |
| Known as | DNRII-LSTs | “In a dose escalation study, eight patients with Epstein Barr virus-positive Hodgkin lymphoma received two to 12 doses of between 2 × 107 and 1.5 × 108 cells/m2 of...” PMID 29315015 ↗ Jan 2018 |
| Action | Inhibit | “forced expression of a dominant-negative TGF-β receptor type 2 (DNRII)” PMID 29315015 ↗ Jan 2018 |
| Modality | Cell therapy | “special immune system cells called TGFb-resistant LMP-specific cytotoxic T lymphocytes (DNR-CTL), a new experimental therapy.” NCT00368082 ↗ |
| Route | Intravenous | “CTLs be given by intravenous injection over 1-10 minutes” NCT00368082 ↗ |